AmerisourceBergen Corporation

This is our first report on major pharmaceutical sourcing and distribution services provider, AmerisourceBergen. The company produced strong financial results in the first quarter of fiscal 2023, with revenue of approximately $63 billion, reflecting 5% year-over-year growth and adjusted EPS growth of 5%. It managed to deliver an all-around beat and continued to maintain its dominant market position. Their fundamentals remain solid as they continue to focus on providing a differentiated value proposition to their clients and partners across the healthcare value chain. Among major updates, AmerisourceBergen added PharmaLex to its portfolio of specialty solutions to expand its capabilities. The management believes that the acquisition of PharmaLex will help the company assist pharma and biotech companies. We initiate coverage on the stock of AmerisourceBergen Corporation with a ‘Buy’ rating.